利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.015 秒)

    Sustained release formulations of oxymorphone
    3.
    发明申请
    Sustained release formulations of oxymorphone 审中-公开
    羟吗啡酮的缓释制剂

    公开(公告)号：US20080050431A1

    公开(公告)日：2008-02-28

    申请号：US11891775

    申请日：2007-08-13

    申请人： Anand Baichwal ,  Huai-Hung Kao ,  Troy McCall

    发明人： Anand Baichwal ,  Huai-Hung Kao ,  Troy McCall

    IPC分类号： A61K9/22 ,  A61K31/485 ,  A61P29/00

    CPC分类号： A61K31/485 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2054

    摘要： Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.

    摘要翻译： 羟吗啡酮或其药学上可接受的盐的缓释制剂; 制备羟吗啡酮缓释制剂或其药学上可接受的盐的方法; 提供了使用羟吗啡酮的缓释制剂或其药学上可接受的盐来治疗患有疼痛的患者的方法。

    Sustained release matrix systems for highly soluble drugs
    8.
    发明申请
    Sustained release matrix systems for highly soluble drugs 有权
    用于高度可溶性药物的持续释放基质体系

    公开(公告)号：US20070218137A1

    公开(公告)日：2007-09-20

    申请号：US11729024

    申请日：2007-03-27

    申请人： Anand Baichwal ,  Troy McCall ,  Lirong Liu ,  Steve Labudzinski

    发明人： Anand Baichwal ,  Troy McCall ,  Lirong Liu ,  Steve Labudzinski

    IPC分类号： A61K9/00

    CPC分类号： A61K31/554 ,  A61K9/167 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2077 ,  A61K9/2846 ,  A61K9/2866

    摘要： Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing a sustained release of said medicament after oral administration to human patients.

    摘要翻译： 公开了持续释放的口服固体剂型，其包含治疗有效量的溶解度大于约10g / l的药物; pH调节剂; 以及包含胶凝剂的持续释放基质，所述胶凝剂包含杂多糖胶和能够在暴露于环境流体时交联所述杂多糖胶的均聚糖胶，所述剂型在口服给药后提供所述药物的持续释放 人类病人。